article thumbnail

Ten Ways to Think Differently About Small-to-Mid-Sized Pharma Launches

Eversana Intouch

Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. By 2018, that share had fallen by about half. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled.

Pharma 105
article thumbnail

470% price increases

World of DTC Marketing

Today, AbbVie charges approximately $77,000 for a year’s supply of Humira—470% more than when the drug was launched in 2003. Record Corporate Revenue Driven by Price Increases: Since 2003, AbbVie has collected over $107 billion in U.S. The graph below shows AbbVie’s and Amgen’s pricing for Humira and Enbrel from 2003 to 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Market with Maximum Efficiency by Obeying Your Inner Sensei

PM360

This article will explore how life sciences marketers can increase their competitive advantage by applying the discipline’s basic principles to their own strategies. In terms of branding, this judo principle lies at the nexus of three interrelated concepts: market research, competitive analysis, and brand positioning.

article thumbnail

The 4 Types of Medtech Innovation  

Cesare Ferrari

In the medical device business, the capacity for innovation is commonly regarded as a key competence and a powerful response mechanism for companies operating in our complex and highly competitive environment. The purpose of this post is to help MedTech professionals to better understand the different types of innovation.

article thumbnail

Amarin Makes Moves towards Global Expansion of Vazkepa

Pharmaceutical Technology

AstraZeneca ’s cholesterol drug Crestor (rosuvastatin) was approved in 2003 in the US but only approved in Germany in 2008. The company now faces a highly competitive generics market for its lead drug. Amarin’s net product revenue was $577.9 million in 2021 and $607 million in 2020, as per its financial filings.

article thumbnail

Healthcare Price Transparency is Here. Now What?

Clarify Health

In this role, he works closely with the provider partners in their network and has been able to collect several perspectives around price transparency and the impact it may have in a competitive market like Kansas City. ” Reflecting on the highly competitive Kansas City market, Dr. Sweat had a similar take.

article thumbnail

Healthcare Price Transparency is Here. Now What?

Clarify Health

In this role, he works closely with the provider partners in their network and has been able to collect several perspectives around price transparency and the impact it may have in a competitive market like Kansas City. ” Reflecting on the highly competitive Kansas City market, Dr. Sweat had a similar take.